皓宸医疗(002622) - 2024 Q1 - 季度财报

Revenue and Earnings - The company's revenue for Q1 2024 was ¥163,503,563.10, representing a 26.12% increase compared to ¥129,643,591.18 in the same period last year[4] - Total operating revenue for Q1 2024 reached ¥163.50 million, a 26.0% increase from ¥129.64 million in the same period last year[17] - Basic and diluted earnings per share were both ¥-0.0054, reflecting a decrease of 575.00% from ¥-0.0008 in the previous year[4] - Basic and diluted earnings per share for Q1 2024 were both -¥0.0054, compared to -¥0.0008 in Q1 2023[19] Net Loss and Cash Flow - The net loss attributable to shareholders was ¥4,572,538.15, a significant increase of 546.69% from a loss of ¥707,071.25 in the previous year[4] - Net loss for Q1 2024 was ¥7.03 million, compared to a net loss of ¥3.15 million in Q1 2023, representing a 123.5% increase in losses[18] - The net cash flow from operating activities was negative at ¥11,948,253.48, a decline of 451.68% compared to a positive cash flow of ¥3,397,477.87 in the same period last year[4] - The net cash flow from operating activities for Q1 2024 was -11,948,253.48, compared to 3,397,477.87 in Q1 2023[21] - The company reported a substantial increase in cash outflow from operating activities, indicating potential challenges in cash management[21] Expenses - Research and development expenses increased by 138% year-on-year, amounting to an increase of ¥920,000[7] - Research and development expenses rose to ¥1.59 million, a significant increase of 138.0% from ¥0.67 million in the previous year[17] - Sales expenses rose by 53.94%, totaling an increase of ¥14,680,000 due to expanded business operations[7] - Total operating costs increased to ¥179.78 million, up 29.7% from ¥138.69 million year-over-year[17] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,524,563,727.87, a decrease of 0.74% from ¥1,535,890,599.57 at the end of the previous year[4] - The company's total liabilities amounted to ¥1,060.78 million, slightly down from ¥1,070.75 million in the previous quarter[18] - Total current liabilities increased from ¥891,757,164.96 to ¥893,878,877.69, a rise of approximately 0.24%[15] - The company's long-term equity investments increased from ¥476,480,000.00 to ¥486,739,590.13, reflecting a growth of about 2.66%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 43,866[11] - The largest shareholder, Guangzhou Huiyin Rifen Investment Partnership, holds 23.81% of shares, totaling 200,000,000 shares[11] Cash Management - The company's cash and cash equivalents decreased from ¥146,388,361.10 to ¥119,306,297.16, a decline of approximately 18.5%[14] - The total cash and cash equivalents at the end of Q1 2024 were 114,142,407.13, down from 151,186,208.20 at the end of Q1 2023[21] - The cash balance decreased by 27,431,910.18 during the quarter, reflecting liquidity pressures[21] Other Income and Comprehensive Loss - The company reported a decrease in other income by 89.92%, amounting to a reduction of ¥1,830,000 due to decreased government subsidies[7] - Other comprehensive income after tax for the period was ¥0.90 million, compared to a loss of ¥0.03 million in the previous year[19] - The company reported a total comprehensive loss of ¥6.12 million for Q1 2024, compared to a loss of ¥3.18 million in the same period last year[19] Accounting and Reporting - The company did not undergo an audit for the Q1 2024 report[22] - The company is implementing new accounting standards starting in 2024, which may impact future financial reporting[22]